Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06273462 · ClinicalTrials.gov registry record · Phase 2
Palmitoylethanolamide for Chronic Inflammatory Pain Conditions
A Phase 2 study of Chronic Pain, sponsored by Navy Medical Center San Diego.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06273462: Recruiting Phase 2 study of Chronic Pain, sponsored by Navy Medical Center San Diego.
NCT06273462 is a Phase 2 study of Chronic Pain that is actively recruiting participants, run by Navy Medical Center San Diego. The registered enrollment target is 80 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06273462, a Phase 2 study of Chronic Pain, is actively recruiting participants, sponsored by Navy Medical Center San Diego.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide (PEA) is effective in reducing the pain in patients with chronic inflammatory pain conditions. The main question the trial aims to answer is if PEA works better at treating a patients pain and improving their function better than a placebo. Participants will be divided into two equal groups and asked to take either PEA or a placebo for 8 weeks.
Conditions Studied
Interventions
- OTHER placebo
- DRUG Palmitoylethanolamide 600mg twice a day
Study Locations (1)
California
- Naval Medical Center San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-08-05 |
| Est. Completion | 2025-10-30 |
| Phase | Phase 2 |
What NCT06273462 shows while recruiting
NCT06273462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT06273462 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06273462 about?
NCT06273462 is a clinical study titled "Palmitoylethanolamide for Chronic Inflammatory Pain Conditions". The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide (PEA) is effective in reducing the pain in patients with chronic inflammatory pain conditions. The main question the trial aims to answer is if PEA works better at treating a patients pain and improving their...
What is the current status of trial NCT06273462?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-08-05. Estimated completion is 2025-10-30.
What conditions does trial NCT06273462 study?
This clinical trial studies the following conditions: Chronic Pain.
What interventions are being tested in trial NCT06273462?
The interventions under investigation include: placebo (OTHER), Palmitoylethanolamide 600mg twice a day (DRUG).
Who is sponsoring clinical trial NCT06273462?
This trial is sponsored by Navy Medical Center San Diego, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06273462 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06273462's enrollment target sits among peer trials
80 150th of 301 higher than 148 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product
RECRUITING · Phase 2
-
The Role of Brain Dopamine in Chronic Pain
RECRUITING · Phase 2
-
Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
Dronabinol as an Adjunct for Reducing Pain
RECRUITING · Phase 2
-
Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI